Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, June 24 at 2:00 PM EDT

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on May 21, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Development of 3D Human Blood Brain Barrier Formation Assay

Closed
FDA_5212026Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 54171
New
Federal
N0016425SC001 CSOThe contract N0016425SC001, issued by the Naval Surface Warfare Center, Crane Division under the Department of Defense, is a Commercial Solutions Opening (CSO) aimed at rapidly acquiring innovative commercial products or services applicable to defense needs, particularly in expeditionary warfare, strategic missions, and electromagnetic warfare. This competitive CSO uses a three-phased selection process consisting of Solution Brief submissions, Pitch presentations, and Full written proposals to identify and rapidly prototype technologies that address specific Areas of Interest (AOIs). The contract leverages Other Transaction Authority (OTA) under 10 U.S.C. § 4022, allowing flexible agreements with industry partners to prototype cutting-edge technologies with a focus on integration, operational agility, and modernization. Amendments to the solicitation have extended proposal submission deadlines and added new AOIs covering technologies such as miniature aiming systems, lightweight machine gun systems, and modular optics, reflecting a continual evolution of capability requirements. Solicitations under this CSO are fixed-price, and awards will be made only to responsible offerors registered in SAM with a DUNS number and CAGE code. The selection is merit-based, prioritizing technical relevance, feasibility, and innovation over cost, though pricing reasonableness and delivery schedule are also considerations. Proposers must submit unclassified materials, with explicit provision for protecting proprietary information, and may expect evaluation by government and vetted non-government experts under strict confidentiality agreements. Successful prototype projects may lead to follow-on production contracts without further competition, accelerating the transition of proven technologies into operational use. Submissions undergo rigorous evaluation that considers relevancy to AOIs, technical soundness, and promoter capabilities, with iterative prototyping encouraged to refine and adapt solutions during development. Government inspection and acceptance occur primarily at the NSWC Crane facilities or other designated government-controlled sites, ensuring compliance with performance metrics and readiness for operational integration. Overall, this contract facilitates a streamlined channel for commercial entities, including nontraditional defense contractors and small businesses, to contribute innovative solutions addressing key national defense priorities.
Nswc Crane

POSTED

5 days ago

DEADLINE

in 2 days
NAICS: 54171
New
Federal
N0016426SCA007 - Flyweight Assault Machine Gun (FAMG) AOIUSSOCOM, through NSWC Crane, is soliciting proposals for a lightweight, man-portable, belt-fed 5.56x45mm weapon to replace the aging MK46 series. The new Flyweight Assault Machine Gun (FAMG) aims to leverage advancements in materials, manufacturing, and technology for superior operational performance. Key requirements include a maximum weight of 11.5 lbs (goal of 10 lbs), a length not exceeding 39 inches (goal of 35 inches), and effective range of at least 500 meters. Reliability standards demand a Minimum Round Between Stoppages (MRBS) of 1,400 rounds and Mean Round Between Failures (MRBF) thresholds of 1,800 and 15,000 rounds, respectively. The weapon must integrate seamlessly with USSOCOM’s existing Visual Augmentation Systems and Weapon Accessories (VASWA), and support features such as quick barrel changes, various firing modes, and compatibility with multiple aiming and fire control systems. The evaluation process includes submission of white papers by June 18, 2026, virtual pitch presentations, and prototype proposal requests, following the established Commercial Solutions Opening (CSO) process detailed in NSWC Crane CSO N0016425SC0001. Proposers are expected to detail cost estimates, development timelines, and technical readiness levels (minimum TRL 7), alongside images of the proposed design. The contract encourages participation from nontraditional defense contractors, small businesses, or entities contributing significant non-federal funding. Successful prototype development may lead to follow-on production contracts without further competitive procedures, potentially involving multiple Department of Defense organizations. Confidentiality of proprietary information is emphasized throughout, and points of contact are provided for inquiries and submissions.
Nswc Crane

POSTED

6 days ago

DEADLINE

in 1 day

AI Contract Overview

Show more

The Food and Drug Administration (FDA) plans to issue a sole source firm fixed price purchase order to MIMETAS B.V., located in Gaithersburg, Maryland, for the development of a 3D human blood-brain barrier formation assay. This procurement follows FAR Part 6.302-1(a)(2)(ii), indicating that MIMETAS B.V. is the only responsible source capable of fulfilling the agency’s specific requirement. The notice serves to inform the public of this anticipated award and is not a solicitation for competitive proposals. However, any interested party believing they can meet the stated requirements may submit a written capability statement by June 12, 2026, at 3:00 PM EST for consideration, although the government reserves the right to proceed with the sole source award if no other capable source is identified. The project is set under NAICS code 54171 and managed by the FDA Office of Acquisition and Grant Services within the Department of Health and Human Services. The place of performance is Silver Spring, Maryland. Interested respondents should submit their capability statements via email to the contract specialist, Hilda Aryeh. The anticipated award is expected within approximately ten days following the notice unless the government determines otherwise based on received submissions. Additional details, including the statement of work, are provided in the attached documentation to the notice.

General Info

FDA to award sole source fixed price contract to MIMETAS B.V. for 3D blood-brain barrier assay.

Agency

Department Of Health And Human Services → FDA Office Of Acq Grant Svcs

NAICS

Place of Performance

Silver Spring, MD, USA

Set-Aside

NONE

Documents

(1)

Draft Statement of Work for Blood-Brain Barrier Model Development

PDFsow

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs
Contacts1 person available
OfficeRockville, MD, 20852, USA
Organization / Agency
Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
Office AddressRockville, MD, 20852, USA
Contacts

Full Description

Show more

The Food and Drug Administration (FDA) intends to award a Sole Source Firm Fixed Price Purchase order to MIMETAS B.V.  704 Quince Orchard RD, Suite 260 Gaithersburg, Maryland 20878-1752.


In accordance with FAR Part 6.302-1 (a) (2)(ii) which states” Only one responsible source and no other supplies or services will satisfy agency requirement”.



The purpose of this notice is to inform the public that the Food and Drug Administration (FDA) anticipates issuing a Firm Fixed Price Purchase Order.



MINIMUM REQUIREMENTS:




See Attached Statement of Work


This notice is not a request for competitive proposals. However, any party that believes it can meet this requirement as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to perform the requirement.


Capability statements must be received by the response date and time of this notice. Submissions will be reviewed to determine if they can meet the requirement. A determination by the Government to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.


It is anticipated that an award will be issued to MIMETAS B.V. within approximately ten (10) days after the date of this notice unless the Government determines that any other organization has the capability to meet this requirement.


Response Date: June 12, 2026, by 3.00PM EST. Please email responses to Hilda Aryeh –hilda.aryeh@fda.hhs.gov.


Hilda Aryeh


Contract Specialist